In the non-profit world, he currently serves as trustee to The Academy of Natural, Lankenau Medical Center, Lankenau Institute of Medical Research, the Mount Desert Island Biological Laboratory, and the Wistar Institute. He is the Founder and CEO of The Cotswold Foundation and is the author of Adventures in Investing, which describes his career in the investment business. Mr. Morris received a bachelor’s degree in Chemistry from Cornell University, an M.B.A. from the Harvard Business School, and holds the CFA designation from the CFA Institute.
Board of Directorsdgalfano
Dr. Reiser joined the company as Board Chairman in 2011. He received his PhD in Physiology from Indiana University School of Medicine and has more than 32 years of pharmaceutical and biotech experience in both public and private companies. He served as President, Chief Executive Officer and a member of the Board of CureDM Inc., a privately held biopharmaceutical company focused on the discovery and development of new therapies that ameliorate or reverse diabetes. From 2003-2008, he was President and Chief Executive Officer and member of the Board of Locus Pharmaceuticals, a computational, small molecule-oriented oncology company. From 1998 to 2002, Dr. Reiser served as President, Chief Executive Officer and member of the Board of Cytogen Corporation, a NASDAQ-traded product based oncology company. Prior to joining Cytogen, Dr. Reiser was Corporate Vice President, General Manager, Pharmaceuticals and member of the Board of Directors for Berlex Laboratories, Inc., the US Subsidiary of Schering AG. During his 17-year tenure at Berlex, he held numerous senior leadership positions, including serving as the first President of Schering Berlin’s Venture Corporation. He has served on numerous boards and as Chairman of the New Jersey Biotechnology Council from 2001 to 2002. Currently he is active on five corporate boards and is also a member of the Board and Executive Committee of the Pennsylvania Biotech Association.
Peter E. Grebow, PhD joined the board in 2011. He is President and founder of P.E. Grebow Consulting, Inc., which he formed in 2011. He also serves as Executive Vice President of Research and Development at Eagle Pharmaceuticals, Inc. since October, 2013. From 1991 to 2011, Dr. Grebow held several key positions with Cephalon, Inc. (now Teva Pharmaceuticals), including Executive Vice President, Cephalon Ventures; Executive Vice President, Technical Operations; Senior Vice President, Worldwide Business Development; and Senior Vice President, Drug Development. Prior to joining Cephalon, Dr. Grebow served as the Vice President, Drug Development for Rorer Central Research, a division of Rhone-Poulenc Rorer Pharmaceuticals Inc., a pharmaceutical company, from 1986 to 1990. Dr. Grebow served as a director of Optimer Pharmaceuticals from February 2009 until October, 2013. Dr. Grebow has also served as a director of Q Holdings, Inc. since December 2011 and GenSpera, Inc. since May, 2012. Dr. Grebow is a member of the Investment Advisory Board of the Harrington Discovery Institute since April, 2014. Dr. Grebow received his undergraduate degree from Cornell University, an MS in chemistry from Rutgers University and a PhD in physical biochemistry from the University of California, Santa Barbara.
Mr. Meyer joined the company as a Director in 2012. He has been the Chief Executive Officer of Scientific Health Development (SHD) since its formation in February 2006, and is a General Partner of its most recent fund. SHD is an investment fund focused on earlier stage life science companies and is located in Dallas, Texas. Prior to joining SHD, he was an attorney in private practice for over 12 years, most recently with the Dallas office of Vinson & Elkins L.L.P. Mr. Meyer has a B.B.A. in finance from Texas Christian University and a J.D. from St. Mary’s University School of Law. Mr. Meyer is a director of all SHD portfolio companies.
Ms. Miwa Toyoda joined the board in 2015. She is Principal at JAFCO Co., Ltd., Tokyo-based venture capital firm, where she focuses on investment in US/Japan biotech companies with platform technologies. Prior to joining JAFCO in Dec 2014, she was with ONO Pharmaceutical, where she spent 18 years in various divisions including Business Development and R&D, most recently as Manager of BD with responsibility of search and evaluation of in-licensing candidates and out-licensing activities. She received Master of Pharmaceutical Science degree in Pharmacology at the University of Tokyo.
Mr. Tarnoff joined Complexa in 2011 as Director, President and Chief Executive Officer. Mr. Tarnoff brings 30 years of pharmaceutical experience to his leadership of Complexa. He has built and led business units within large pharma and developed multiple early stage start-ups. His most recent roles include serving as CEO of JDP Therapeutics, CEO of Houston Pharma (and its subsidiary Potomac Pharma), and CCO at ViroPharma. One of his many roles within large pharma was leading a $1.5 billion U.S. business unit at AstraZeneca. He is a recognized industry leader for his expertise in creating successful management teams, building start-up companies, strategic planning and corporate development. Mr. Tarnoff also has a strong record of a series of capital raises. With a career that advanced within the executive ranks of the commercial and operations side of the industry, he brings a unique set of skills that blend clinical and business development activities. Mr. Tarnoff received a bachelor’s degree in Biology from LaSalle University. He is also currently a board member of several early stage healthcare companies.
Mr. I. Wistar Morris joined the board in 2012. He is Senior Investment Consultant to Pennsylvania Trust. In April 2011 he retired from Boenning & Scattergood, an Investment Securities firm, where he served as a Director and Investment Advisor for 20 years. Prior to this, Mr. Morris founded the Morris Investment Management Company and held the roles of President and Chairman. Mr. Morris was also Executive Vice President with the investment management firm Hopper Soliday & Co., spending 15 years there. Mr. Morris has been on the boards of 20 public and private companies.
Dr. Harada has more than 20 years of experience in evaluating medical drug candidates, scientific technology platforms and intellectual property portfolios. In 2004, he joined JAFCO, the largest venture capital firm in Japan, working for the life science investment group as a group leader. In this role, he evaluates US or Japan-based biotech companies for potential investment opportunities, several of which have successfully gone on to become public companies or the subject of significant acquisitions. Prior to JAFCO, Dr. Harada held positions of increasing responsibility within the medical drug and devices division of Toray Industries, Inc., a leading Japanese chemical and fiber company, most recently as manager for collaborative research agreements with a number of leading Japanese academic institutes and biotechnology companies. In addition to his board position at Complexa, Dr. Harada also served on the board of TRACON Pharmaceuticals and Eleven Biotherapeutics. He is an immunologist by training, earning his PhD in pharmacology at the University of Tokyo.